A Randomised Open-Label, Phase 1b Study of the Safety of Pirfenidone Solution for Inhalation (AP01) in Patients with Idiopathic Pulmonary Fibrosis (ATLAS Study)

  • Lake, Fiona (Chief Investigator)

Project Details

StatusActive
Effective start/end date1/05/1931/01/23

Funding

  • Avalyn Pharma: A$26,962.00
  • Avalyn Pharma: A$30,979.00
  • Avalyn Pharma: A$21,527.00
  • Avalyn Pharma: A$20,699.00
  • Avalyn Pharma: A$10,116.00